Target Name: MIR500A
NCBI ID: G574502
Review Report on MIR500A Target / Biomarker Content of Review Report on MIR500A Target / Biomarker
MIR500A
Other Name(s): MicroRNA 500a | MIR500 | hsa-mir-500a | mir-500a | MIRN500 | hsa-miR-500a-5p | hsa-mir-500 | microRNA 500a | hsa-miR-500a-3p

miRNA 500a: A Non-Coding RNA Molecule with Potential Drug Targets and Biomarkers

MicroRNA 500a (miRNA 500a) is a non-coding RNA molecule that plays a crucial role in various biological processes in the human body. It is a key regulator of gene expression and has been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and developmental disorders. In this article, we will explore the biology and significance of miRNA 500a as a drug target and its potential utility as a biomarker.

The discovery and characterization of miRNA 500a

MiRNA 500a was first identified in the Drosophila using RNA interference (RNAi) technology. By RNAi screening, researchers found that a unique microRNA was specifically expressed in the RNAi-induced gene knockdown flies and had a highly enrichment in the RNAi-protected cells . Subsequent experiments using RNA sequencing (RNA-seq) and bioinformatics analysis confirmed that the microRNA was indeed miRNA 500a.

Function and regulation of miRNA 500a

MiRNA 500a is a non-coding RNA molecule that functions as a regulator of gene expression. It is expressed in a variety of tissues and cells in the body and has been implicated in the regulation of various biological processes, including cell growth, apoptosis, migration , and inflammation.

One of the well-documented functions of miRNA 500a is its role in cell apoptosis. miRNA 500a has been shown to induce apoptosis in various cell types, including cancer cells, neurons, and heart cells. This is achieved by targeting specific mRNAs for degradation using the 21-hydroxylase enzyme, which activates the pro-apoptotic protein Bax.

miRNA 500a has also been shown to play a role in the regulation of cell cycle progression. It has been shown to promote the G1 phase and inhibit the S phase, which is necessary for cell growth and progression.

MiRNA 500a has also been linked to inflammation. It has been shown to regulate the expression of pro-inflammatory cytokines, such as TNF-伪, IL-1尾, and IL-6, and to inhibit the production of anti-inflammatory cytokines, such as IL-10.

Disease associations and potential drug targets

MiRNA 500a has been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

In cancer, miRNA 500a has been shown to be downregulated in various cancer types, including breast, ovarian, and colorectal cancers. This has led to the idea that miRNA 500a may be a potential drug target for cancer treatment. Studies have shown that inhibiting miRNA 500a levels can significantly enhance the effectiveness of chemotherapy and radiation therapy in various cancer types.

In neurodegenerative diseases, miRNA 500a has been shown to be involved in the regulation of neurotransmitter synthesis and function. It has been implicated in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In developmental disorders, miRNA 500a has been shown to play a role in the regulation of gene expression and development. It has been implicated in the development of developmental disorders, including Down syndrome and Fragile X syndrome.

In conclusion, miRNA 500a is a non-coding RNA molecule that has been shown to play a crucial role in various biological processes in the human body. Its functions as a regulator of gene expression and its potential involvement in a wide range of diseases make it an attractive drug target and a biomarker for future studies. Further research is needed to fully understand the role of miRNA 500a

Protein Name: MicroRNA 500a

The "MIR500A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR500A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR500B | MIR501 | MIR5010 | MIR5011 | MIR502 | MIR503 | MIR503HG | MIR504 | MIR5047 | MIR505 | MIR506 | MIR507 | MIR508 | MIR5088 | MIR5089 | MIR509-1 | MIR509-2 | MIR509-3 | MIR5090 | MIR5091 | MIR5092 | MIR5093 | MIR5094 | MIR510 | MIR5100 | MIR511 | MIR511-2 | MIR512-1 | MIR512-2 | MIR513A1 | MIR513A2 | MIR513B | MIR513C | MIR514A1 | MIR514A2 | MIR514A3 | MIR514B | MIR515-1 | MIR515-2 | MIR516A1 | MIR516A2 | MIR516B1 | MIR516B2 | MIR517A | MIR517B | MIR517C | MIR5186 | MIR5187 | MIR5188 | MIR5189 | MIR518A1 | MIR518A2 | MIR518B | MIR518C | MIR518D | MIR518E | MIR518F | MIR5190 | MIR5191 | MIR5192 | MIR5193 | MIR5194 | MIR5195 | MIR5196 | MIR5197 | MIR519A1 | MIR519A2 | MIR519B | MIR519C | MIR519D | MIR519E | MIR520A | MIR520B | MIR520C | MIR520D | MIR520E | MIR520F | MIR520G | MIR520H | MIR521-1 | MIR521-2 | MIR522 | MIR523 | MIR524 | MIR525 | MIR526A1 | MIR526A2 | MIR526B | MIR527 | MIR532 | MIR539 | MIR541 | MIR542 | MIR543 | MIR544A | MIR544B | MIR545 | MIR548A1 | MIR548A1HG | MIR548A2